Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study Of Lisaftoclax (APG-2575) In Combination With Azacitidine (AZA) In Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
.